Trial Profile
Phase I/II trial of NSI-566 in patients with amyotrophic lateral sclerosis in Mexico.
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs NSI 566 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 20 Aug 2013 The IND for this trial is expected to be filed in Q3, 2013 according to a Neuralstem media release.
- 20 Mar 2013 New trial record